JAK1
12 drugs Immunology
5
approved indications
12
Approved Drugs
9
Companies
23
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (9 companies)
✓ All 12 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (23 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
AbbVie 2 drugs
Pfizer 2 drugs
INCYTE CORP 2 drugs
By Therapeutic Area
Other 7 drugs
Immunology 5 drugs
By Therapeutic Area
Other 7 drugs
XELJANZ, RINVOQ, JAKAFI, GAVRETO +3 more
Immunology 5 drugs
XELJANZ XR, RINVOQ LQ, OLUMIANT, OPZELURA +1 more
Indications Treated
Moderately to severely active rheumatoid arthritisActive psoriatic arthritisActive ankylosing spondylitisModerately to severely active ulcerative colitisActive polyarticular course juvenile idiopathic arthritisRefractory, moderate to severe atopic dermatitisModerately to severely active Crohn’s diseaseAtopic DermatitisVitiligoChronic Hand EczemaMetastatic RET fusion-positive non-small cell lung cancerAdvanced or metastatic RET fusion-positive thyroid cancerRheumatoid ArthritisPsoriatic ArthritisUlcerative ColitisAnkylosing SpondylitisPolyarticular Juvenile Idiopathic ArthritisMyelofibrosisPolycythemia VeraGraft-Versus-Host DiseaseCOVID-19Alopecia AreataAnemia
All Drugs Targeting JAK1
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| XELJANZ | PF PRISM CV | 2012 | 5 | |
| RINVOQ | AbbVie | 2019 | 5 | |
| XELJANZ XR | Pfizer | 2016 | 5 | Immunology |
| RINVOQ LQ | AbbVie | 2024 | 4 | Immunology |
| JAKAFI | INCYTE CORP | 2011 | 3 | |
| OLUMIANT | Eli Lilly | 2018 | 3 | Immunology |
| OPZELURA | INCYTE CORP | 2021 | 2 | Immunology |
| GAVRETO | BLUEPRINT MEDICINES | 2020 | 2 | |
| OJJAARA | GSK | 2023 | 2 | |
| ANZUPGO | LEO PHARMA AS | 2025 | 1 | |
| CIBINQO | Pfizer | 2022 | 1 | Immunology |
| LEQSELVI | Sun Pharma | 2024 | 1 |